T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock Information for T2 Biosystems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About T2 Biosystems Inc.

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems Announces Third Quarter 2024 Financial Results
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
T2 Biosystems to Host Business Update Call on October 10, 2024
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.